« Previous
Next »
Titles
- Radioactive fallout and shelter1
- Rare diseases: considerations for the development of drugs and biological products : guidance for industry1
- Real-time oncology review (RTOR): guidance for industry1
- Real-world data: assessing registries to support regulatory decision-making for drug and biological products : guidance for industry1
- Recommendations for evaluating donor eligibility using individual risk-based questions to reduce the risk of human immunodeficiency virus transmission by blood and blood products: guidance for industry1
- Recommendations to reduce the risk of transfusion-transmitted malaria: guidance for industry1
- Recommended statement for over-the-counter aspirin-containing drug products labeled with cardiovascular related imagery1
- Recurrent herpes labialis: developing drugs for treatment and prevention1
- Referencing the definition of “device” in the Federal Food, Drug, and Cosmetic Act in guidance, regulatory documents, communications, and other public documents: guidance for industry and Food and Drug Administration staff1
- Reformulating drug products that contain carbomers manufactured with benzene: guidance for industry1
- Refusal of inspection by a foreign food establishment or foreign government: guidance for industry1
- Registration and listing of cosmetic product facilities and products: guidance for industry1
- Registration and product listing for owners and operators of domestic tobacco product establishments: (revised)1
- Regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps): small entity compliance guide : guidance for industry1
- Regulations and procedure1
- Regulations and system of ethics of the Medical Association of Washington2
- Regulatory classification of pharmaceutical co-crystals1
- Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use : guidance for industry and Food and Drug Administration staff1
- Replacement reagent and instrument family policy for in vitro diagnostic devices: guidance for industry and Food and Drug Administration staff1
- Report1